Robitussin Recall: Contaminated Products Prompt Health Alert in Washington Parish
Published 4:07 pm Friday, January 26, 2024
WASHINGTON PARISH, La. – In a recent announcement, Warren, NJ-based company Haleon has issued a voluntary recall of certain batches of Robitussin Honey CF Max Day Adult and Robitussin Honey CF Max Nighttime Adult cough syrups. The recall, initiated on January 24, 2024, stems from concerns over microbial contamination.
The recall affects eight specific lots of the cough syrup products, identified by their lot numbers and expiry dates, as listed below:
– Robitussin Honey CF Max Day Adult 4oz: Lot Number T10810, Expiry Date 31OCT2025
– Robitussin Honey CF Max Day Adult 8oz: Lot Numbers T08730, T08731, T08732, T08733, T10808, Expiry Dates 31MAY2025, 31MAY2025, 31MAY2025, 31MAY2025, 30SEP2025
– Robitussin Honey CF Max Nighttime Adult 8oz: Lot Numbers T08740, T08742, Expiry Dates 30JUN2026, 30JUN2026
The reason for the recall, according to Haleon, is the potential risk of microbial contamination. While the company has not received any reports of adverse events related to the affected products, they are taking proactive measures to ensure consumer safety.
In a statement, the company highlighted that in immunocompromised individuals, the use of the contaminated product could lead to severe or life-threatening adverse events, such as fungemia or disseminated fungal infection. While the risk to non-immunocompromised consumers is lower, the possibility of an infection necessitating medical intervention cannot be completely ruled out.
Consumers who have purchased any of the recalled products are urged to discontinue use immediately. Haleon has notified distributors and customers directly, providing instructions for the return of the affected products. Consumers with questions or concerns can contact the company’s Consumer Relations team at +1-800-245-1040 (Monday through Friday, 8 AM to 6 PM Eastern Time) or via email at firstname.lastname@example.org.
Individuals who have experienced any problems possibly linked to the use of these cough syrups are advised to consult their physician or healthcare provider. Adverse reactions or quality issues associated with the products can also be reported to the FDA’s MedWatch Adverse Event Reporting program online, by regular mail, or by fax.
This recall is being conducted with the cooperation of the U.S. Food and Drug Administration (FDA), which emphasizes that the FDA does not endorse the product or the company but posts such announcements as a public service to ensure consumer safety.